Coagulation in Liver Disease

Abstract

The liver plays a key role in hemostasis as the site of synthesis of many of the proteins involved in the coagulation, antithrombotic and fibrinolytic systems that interact to both establish hemostasis, and preventing thrombosis. The common laboratory tests, prothrombin time (PT) and activated partial thromboplastin time (aPTT), evolved from studies of plasma clotting in test tubes. Such studies laid the basis for the coagulation cascade model of hemostasis. However, thought has evolved to place a greater emphasis on the active roles of cells in localizing and regulating hemostasis. The PT and aPTT do not reflect the roles of cellular elements in hemostasis, nor do they reflect the crucial roles of antithrombotic and fibrinolytic systems. Thus, though the PT may indeed reflect the synthetic capacity of the liver, it does not accurately reflect the risk of bleeding or thrombosis in patients with liver failure.

Keywords

cirrhosis - thrombin generation - prothrombin time - fibrinolysis

• References

• 1 Quick AJ. The development and use of the prothrombin tests. Circulation 1959; 19 (1) 92-96
• 2 Smith HP, Warner ED, Brinkhous KM. Prothrombin deficiency and the bleeding tendency in liver injury (chloroform intoxication). J Exp Med 1937; 66 (6) 801-811
• 3 Patek AJ, Stetson RP. Hemophilia. I. The abnormal coagulation of the blood and its relation to the blood platelets. J Clin Invest 1936; 15 (5) 531-542
• 4 Owren PA. Parahaemophilia; haemorrhagic diathesis due to absence of a previously unknown clotting factor. Lancet 1947; 1 (6449) 446-448
• 5 Alexander B, Goldstein R, Landwehr G, Cook CD. Congenital SPCA deficiency: a hitherto unrecognized coagulation defect with hemorrhage rectified by serum and serum fractions. J Clin Invest 1951; 30 (6) 596-608
• 6 Biggs R, Douglas AS, MacFarlane RG, Dacie JV, Pitney WR , Merskey. Christmas disease: a condition previously mistaken for haemophilia. BMJ 1952; 2 (4799) 1378-1382
• 7 Aggeler PM, White SG, Glendening MB, Page EW, Leake TB, Bates G. Plasma thromboplastin component (PTC) deficiency; a new disease resembling hemophilia. Proc Soc Exp Biol Med 1952; 79 (4) 692-694
• 8 Rosenthal RL, Dreskin OH, Rosenthal N. New hemophilia-like disease caused by deficiency of a third plasma thromboplastin factor. Proc Soc Exp Biol Med 1953; 82 (1) 171-174
• 9 Langdell RD, Wagner RH, Brinkhous KM. Effect of antihemophilic factor on one-stage clotting tests; a presumptive test for hemophilia and a simple one-stage antihemophilic factor assay procedure. J Lab Clin Med 1953; 41 (4) 637-647
• 10 Margolis J. The kaolin clotting time; a rapid one-stage method for diagnosis of coagulation defects. J Clin Pathol 1958; 11 (5) 406-409
• 11 MacFarlane RG. An enzyme cascade in the blood clotting mechanism, and its function as a biological amplifier. Nature 1964; 202: 498-499
• 12 Davie EW, Ratnoff OD. Waterfall sequence for intrinsic blood clotting. Science 1964; 145 (3638) 1310-1312
• 13 Chargaff E, Bancroft FW, Stanley-Brown M. Studies on the chemistry of blood coagulation III. The chemical constituents of blood platelets and their role in blood clotting, with remarks on the activation of clotting by lipids. J Biol Chem 1936; 116: 237-251
• 14 Bizzozero J. Ueber einen neuen formbestandtheil des blutes und dessen rolle bei der thrombose und der butgerinnung. Virchows Arch Pathol Anat Physiol Klin Med 1882; 90: 261-332
• 15 Hayem G. Recherches sur l'évolution des hématies dans le sang de l'homme et des vertébrés. Arch Physiol 1879; 2: 201-261
• 16 Hoffman M, Monroe III DM. A cell-based model of hemostasis. Thromb Haemost 2001; 85 (6) 958-965
• 17 Drake TA, Morrissey JH, Edgington TS. Selective cellular expression of tissue factor in human tissues. Implications for disorders of hemostasis and thrombosis. Am J Pathol 1989; 134 (5) 1087-1097
• 18 Fleck RA, Rao LV, Rapaport SI, Varki N. Localization of human tissue factor antigen by immunostaining with monospecific, polyclonal anti-human tissue factor antibody. Thromb Res 1990; 59 (2) 421-437
• 19 Rao LV, Rapaport SI. Activation of factor VII bound to tissue factor: a key early step in the tissue factor pathway of blood coagulation. Proc Natl Acad Sci U S A 1988; 85 (18) 6687-6691
• 20 Hoffman M, Colina CM, McDonald AG, Arepally GM, Pedersen L, Monroe DM. Tissue factor around dermal vessels has bound factor VII in the absence of injury. J Thromb Haemost 2007; 5 (7) 1403-1408
• 21 Østerud B, Rapaport SI. Activation of factor IX by the reaction product of tissue factor and factor VII: additional pathway for initiating blood coagulation. Proc Natl Acad Sci U S A 1977; 74 (12) 5260-5264
• 22 Tracy PB, Rohrbach MS, Mann KG. Functional prothrombinase complex assembly on isolated monocytes and lymphocytes. J Biol Chem 1983; 258 (12) 7264-7267
• 23 Le DT, Borgs P, Toneff TW, Witte MH, Rapaport SI. Hemostatic factors in rabbit limb lymph: relationship to mechanisms regulating extravascular coagulation. Am J Physiol 1998; 274 (3, Pt 2) H769-H776
• 24 Bauer KA, Mannucci PM, Gringeri A , et al. Factor IXa-factor VIIIa-cell surface complex does not contribute to the basal activation of the coagulation mechanism in vivo. Blood 1992; 79 (8) 2039-2047
• 25 Ayombil F, Abdalla S, Tracy PB, Bouchard BA. Proteolysis of plasma-derived factor V following its endocytosis by megakaryocytes forms the platelet-derived factor V/Va pool. J Thromb Haemost 2013; 11 (8) 1532-1539
• 26 Hung DT, Vu TK, Wheaton VI, Ishii K, Coughlin SR. Cloned platelet thrombin receptor is necessary for thrombin-induced platelet activation. J Clin Invest 1992; 89 (4) 1350-1353
• 27 Hoffman M, Monroe DM, Roberts HR. Cellular interactions in hemostasis. Haemostasis 1996; 26 (Suppl. 01) 12-16
• 28 Oliver JA, Monroe DM, Roberts HR, Hoffman M. Thrombin activates factor XI on activated platelets in the absence of factor XII. Arterioscler Thromb Vasc Biol 1999; 19 (1) 170-177
• 29 Baglia FA, Walsh PN. Prothrombin is a cofactor for the binding of factor XI to the platelet surface and for platelet-mediated factor XI activation by thrombin. Biochemistry 1998; 37 (8) 2271-2281
• 30 Léon M, Aiach M, Coezy E, Guennec JY, Fiessinger JN. Antithrombin III synthesis in rat liver parenchymal cells. Thromb Res 1983; 30 (4) 369-375
• 31 Bajaj MS, Kuppuswamy MN, Saito H, Spitzer SG, Bajaj SP. Cultured normal human hepatocytes do not synthesize lipoprotein-associated coagulation inhibitor: evidence that endothelium is the principal site of its synthesis. Proc Natl Acad Sci U S A 1990; 87 (22) 8869-8873
• 32 Franssen J, Salemink I, Willems GM, Wun TC, Hemker HC, Lindhout T. Prothrombinase is protected from inactivation by tissue factor pathway inhibitor: competition between prothrombin and inhibitor. Biochem J 1997; 323 (Pt 1) 33-37
• 33 Lu G, Broze Jr GJJ, Krishnaswamy S. Formation of factors IXa and Xa by the extrinsic pathway: differential regulation by tissue factor pathway inhibitor and antithrombin III. J Biol Chem 2004; 279 (17) 17241-17249
• 34 de Agostini AI, Watkins SC, Slayter HS, Youssoufian H, Rosenberg RD. Localization of anticoagulantly active heparan sulfate proteoglycans in vascular endothelium: antithrombin binding on cultured endothelial cells and perfused rat aorta. J Cell Biol 1990; 111 (3) 1293-1304
• 35 Zhang J, Piro O, Lu L, Broze Jr GJ. Glycosyl phosphatidylinositol anchorage of tissue factor pathway inhibitor. Circulation 2003; 108 (5) 623-627
• 36 Hirsh J, Piovella F, Pini M. Congenital antithrombin III deficiency. Incidence and clinical features. Am J Med 1989; 87 (3B): 34S-38S
• 37 Huang ZF, Higuchi D, Lasky N, Broze Jr GJ. Tissue factor pathway inhibitor gene disruption produces intrauterine lethality in mice. Blood 1997; 90 (3) 944-951
• 38 Fair DS, Marlar RA. Biosynthesis and secretion of factor VII, protein C, protein S, and the Protein C inhibitor from a human hepatoma cell line. Blood 1986; 67 (1) 64-70
• 39 Esmon CT, Stenflo J, Suttie JW. A new vitamin K-dependent protein. A phospholipid-binding zymogen of a serine esterase. J Biol Chem 1976; 251 (10) 3052-3056
• 40 Camire RM, Kalafatis M, Simioni P, Girolami A, Tracy PB. Platelet-derived factor Va/Va Leiden cofactor activities are sustained on the surface of activated platelets despite the presence of activated protein C. Blood 1998; 91 (8) 2818-2829
• 41 Esmon CT. The endothelial protein C receptor. Curr Opin Hematol 2006; 13 (5) 382-385
• 42 Cadroy Y, Diquélou A, Dupouy D , et al. The thrombomodulin/protein C/protein S anticoagulant pathway modulates the thrombogenic properties of the normal resting and stimulated endothelium. Arterioscler Thromb Vasc Biol 1997; 17 (3) 520-527
• 43 Esmon CT, Esmon NL, Harris KW. Complex formation between thrombin and thrombomodulin inhibits both thrombin-catalyzed fibrin formation and factor V activation. J Biol Chem 1982; 257 (14) 7944-7947
• 44 Dahlbäck B. Progress in the understanding of the protein C anticoagulant pathway. Int J Hematol 2004; 79 (2) 109-116
• 45 Oliver JA, Monroe DM, Church FC, Roberts HR, Hoffman M. Activated protein C cleaves factor Va more efficiently on endothelium than on platelet surfaces. Blood 2002; 100 (2) 539-546
• 46 Allaart CF, Poort SR, Rosendaal FR, Reitsma PH, Bertina RM, Briët E. Increased risk of venous thrombosis in carriers of hereditary protein C deficiency defect. Lancet 1993; 341 (8838) 134-138
• 47 Comp PC, Nixon RR, Cooper MR, Esmon CT. Familial protein S deficiency is associated with recurrent thrombosis. J Clin Invest 1984; 74 (6) 2082-2088
• 48 Bouwens EA, Stavenuiter F, Mosnier LO. Mechanisms of anticoagulant and cytoprotective actions of the protein C pathway. J Thromb Haemost 2013; 11 (Suppl. 01) 242-253
• 49 Bernard GR, Vincent JL, Laterre PF , et al; Recombinant human protein C Worldwide Evaluation in Severe Sepsis (PROWESS) study group. Efficacy and safety of recombinant human activated protein C for severe sepsis. N Engl J Med 2001; 344 (10) 699-709
• 50 Chesebro BB, Rahn P, Carles M , et al. Increase in activated protein C mediates acute traumatic coagulopathy in mice. Shock 2009; 32 (6) 659-665
• 51 Ndonwi M, Broze Jr G. Protein S enhances the tissue factor pathway inhibitor inhibition of factor Xa but not its inhibition of factor VIIa-tissue factor. J Thromb Haemost 2008; 6 (6) 1044-1046
• 52 Hackeng TM, Rosing J. Protein S as cofactor for TFPI. Arterioscler Thromb Vasc Biol 2009; 29 (12) 2015-2020
• 53 Wood JP, Bunce MW, Maroney SA, Tracy PB, Camire RM, Mast AE. Tissue factor pathway inhibitor-alpha inhibits prothrombinase during the initiation of blood coagulation. Proc Natl Acad Sci U S A 2013; 110 (44) 17838-17843
• 54 Loskutoff DJ, Sawdey M, Keeton M, Schneiderman J. Regulation of PAI-1 gene expression in vivo. Thromb Haemost 1993; 70 (1) 135-137
• 55 Palomo I, Alarcón M, Moore-Carrasco R, Argilés JM. Hemostasis alterations in metabolic syndrome [review]. Int J Mol Med 2006; 18 (5) 969-974
• 56 Iwaki T, Tanaka A, Miyawaki Y , et al. Life-threatening hemorrhage and prolonged wound healing are remarkable phenotypes manifested by complete plasminogen activator inhibitor-1 deficiency in humans. J Thromb Haemost 2011; 9 (6) 1200-1206
• 57 Jennings I, Calne RY, Baglin TP. Predictive value of von Willebrand factor to ristocetin cofactor ratio and thrombin-antithrombin complex levels for hepatic vessel thrombosis and graft rejection after liver transplantation. Transplantation 1994; 57 (7) 1046-1051
• 58 Quick A, Stanley-Brown M, Bancroft F. A study of the coagulation defect in hemophilia and in jaundice. Am J Med Sci 1935; 190: 501-511
• 59 De Caterina M, Tarantino G, Farina C , et al. Haemostasis unbalance in Pugh-scored liver cirrhosis: characteristic changes of plasma levels of protein C versus protein S. Haemostasis 1993; 23 (4) 229-235
• 60 Raya-Sánchez JM, González-Reimers E, Rodríguez-Martín JM , et al. Coagulation inhibitors in alcoholic liver cirrhosis. Alcohol 1998; 15 (1) 19-23
• 61 Butenas S, van't Veer C, Mann KG. “Normal” thrombin generation. Blood 1999; 94 (7) 2169-2178
• 62 Horne III MK, Merryman PK, Cullinane AM, Nghiem K, Alexander HR. The impact of major surgery on blood coagulation factors and thrombin generation. Am J Hematol 2007; 82 (9) 815-820
• 63 Tripodi A, Chantarangkul V, Primignani M , et al. Thrombin generation in plasma from patients with cirrhosis supplemented with normal plasma: considerations on the efficacy of treatment with fresh-frozen plasma. Intern Emerg Med 2012; 7 (2) 139-144
• 64 Gatt A, Riddell A, Calvaruso V, Tuddenham EG, Makris M, Burroughs AK. Enhanced thrombin generation in patients with cirrhosis-induced coagulopathy. J Thromb Haemost 2010; 8 (9) 1994-2000
• 65 Hemker HC, Giesen P, Al Dieri R , et al. Calibrated automated thrombin generation measurement in clotting plasma. Pathophysiol Haemost Thromb 2003; 33 (1) 4-15
• 66 Dargaud Y, Luddington R, Gray E , et al. Standardisation of thrombin generation test—which reference plasma for TGT? An international multicentre study. Thromb Res 2010; 125 (4) 353-356
• 67 Dargaud Y, Wolberg AS, Luddington R , et al. Evaluation of a standardized protocol for thrombin generation measurement using the calibrated automated thrombogram: an international multicentre study. Thromb Res 2012; 130 (6) 929-934
• 68 Caldwell SH, Hoffman M, Lisman T , et al; Coagulation in Liver Disease Group. Coagulation disorders and hemostasis in liver disease: pathophysiology and critical assessment of current management. Hepatology 2006; 44 (4) 1039-1046
• 69 Tripodi A, Mannucci PM. The coagulopathy of chronic liver disease. N Engl J Med 2011; 365 (2) 147-156
• 70 Tripodi A, Primignani M, Chantarangkul V , et al. Thrombin generation in patients with cirrhosis: the role of platelets. Hepatology 2006; 44 (2) 440-445
• 71 Lisman T, Bongers TN, Adelmeijer J , et al. Elevated levels of von Willebrand Factor in cirrhosis support platelet adhesion despite reduced functional capacity. Hepatology 2006; 44 (1) 53-61
• 72 Ben-Ari Z, Osman E, Hutton RA, Burroughs AK. Disseminated intravascular coagulation in liver cirrhosis: fact or fiction?. Am J Gastroenterol 1999; 94 (10) 2977-2982
• 73 Violi F, Ferro D, Basili S , et al. Association between low-grade disseminated intravascular coagulation and endotoxemia in patients with liver cirrhosis. Gastroenterology 1995; 109 (2) 531-539
• 74 Tripodi A, Primignani M, Chantarangkul V , et al. An imbalance of pro- vs anti-coagulation factors in plasma from patients with cirrhosis. Gastroenterology 2009; 137 (6) 2105-2111
• 75 Francis Jr RB, Feinstein DI. Clinical significance of accelerated fibrinolysis in liver disease. Haemostasis 1984; 14 (6) 460-465
• 76 Hersch SL, Kunelis T, Francis Jr RB. The pathogenesis of accelerated fibrinolysis in liver cirrhosis: a critical role for tissue plasminogen activator inhibitor. Blood 1987; 69 (5) 1315-1319
• 77 Ferguson JW, Helmy A, Ludlam C, Webb DJ, Hayes PC, Newby DC. Hyperfibrinolysis in alcoholic cirrhosis: relative plasminogen activator inhibitor type 1 deficiency. Thromb Res 2008; 121 (5) 675-680
• 78 Violi F, Ferro D. Clotting activation and hyperfibrinolysis in cirrhosis: implication for bleeding and thrombosis. Semin Thromb Hemost 2013; 39 (4) 426-433
• 79 Tripodi A, Chantarangkul V, Primignani M , et al. The international normalized ratio calibrated for cirrhosis (INR(liver)) normalizes prothrombin time results for model for end-stage liver disease calculation. Hepatology 2007; 46 (2) 520-527